https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/cardiovascular

The Latest

woman with doctor looking at prescription bottle

This Week in HIV Research: Every Prescription Can Use a Good Steward

Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds Img

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds

Many people who had high lipid levels while taking common HIV treatment regimens that included a protease inhibitor, such as Prezista or Reyataz, saw remarkable improvements after the switch.

Promo Image

Warning Against Using Erythromycin (Even Orally) While Using Protease Inhibitors or Certain Other Drugs

An article in the September 9, 2004 New England Journal of Medicine reported that patients using the antibiotic erythromycin at the same time as drugs that strongly inhibited cytochrome P-450 3A (CYP3A, an enzyme in the liver that helps remove many d...

Promo Image

Protease Inhibitors Appear More Likely to Cause Atherosclerosis Than NNRTIs

Most protease inhibitors (PIs) have been associated with abnormal lipid profiles and insulin resistance, whereas better lipid profiles (such as an increase in high-density lipoprotein [HDL]) are seen with non-nucleoside reverse transcriptase inhibi...

Promo Image

Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression

Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV Patients With Undetectable Viral Load (Poster 590) Authored by P. Gil, M. Górgolas, V. Estrada, A. Arranz, P. Rivas, C. Yera, R. García Delgado, J.J. Granizo, M....

Promo Image

Older PIs Linked to Early Coronary Artery Disease

Reported series of patients have suggested that HIV-infected patients are at an increased risk of coronary artery disease (CAD), linked to the hyperlipidemia and insulin resistance associated with protease-inhibitor therapy. However, necropsy studies...

Promo Image

Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD)

Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) Abstract 34 Authored by F. van Leth1, N. Friis-Møller2, R. Weber, A. d'Arminio Monforte, O. Kirk, R. Thiebaut, L. Morfeldt,...